Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951821 | 0.85 | ACHE (0.58) | ACHECA1CA2MEN1KMT2A | |
| SCHEMBL5951967 | 0.82 | ABCB1 (0.44) | ACHEBRD4CREBBPCA1CA2 | |
| SCHEMBL5952380 | 0.80 | ACHE (0.68) | ACHEHSD17B10POLB | |
| SCHEMBL8167082 | 0.78 | ABCB1 (0.41) | ACHEBRD4CREBBPCA1CA2 | |
| SCHEMBL5951706 | 0.78 | ACHE (0.60) | ACHEBRD4CREBBPALDH1A1HSD17B10 | |
| SCHEMBL5952755 | 0.77 | ACHE (0.67) | ACHEMEN1KMT2AALDH1A1HTT | |
| SCHEMBL22882716 | 0.75 | ALDH1A1 (0.57) | BRD4CA1CA2MEN1KMT2A | |
| SCHEMBL5952549 | 0.73 | ACHE (0.60) | ACHEPOLB | |
| SCHEMBL1838503 | 0.71 | ALDH1A1 (0.53) | BRD4MEN1KMT2AALDH1A1HTT | |
| SCHEMBL30416875 | 0.71 | ALDH1A1 (0.53) | ACHECA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038070-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2006-05-02 | — | — | US | disclosed |
| US-6963017-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-0968158-B1 | METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM | BASELL POLYOLEFINE GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20050033076-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2005-02-10 | — | — | US | disclosed |
| US-20030009046-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033076-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP2J2, IDH3A | ACHE 839/4885BRD4 3097/4885CREBBP 2331/4885 |
| US-20030009046-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP1B1, CYP1A1 | ACHE 820/4885BRD4 3045/4885CREBBP 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.